A RANDOMIZED PHASE II STUDY OF PREOPERATIVE CISPLATIN VS PACLITAXEL IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER WITHOUT GERMLINE BRCA MUTATIONS: EVALUATING THE HOMOLOGOUS RECOMBINATION DEFICIENCY (HRB) BIOMARKER
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
October 1, 2014
End Date
April 30, 2022
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
October 1, 2014
End Date
April 30, 2022